22 results on '"Carlos Alberto Mayo"'
Search Results
2. Género, motivación y actitudes hacia el inglés como lengua extranjera
- Author
-
Julián Andrés Trujillo and Carlos Alberto Mayora
- Subjects
Género ,motivación ,actitudes ,aprendizaje de inglés ,enseñanza de una lengua extranjera ,Special aspects of education ,LC8-6691 ,Language and Literature ,Philology. Linguistics ,P1-1091 - Abstract
Esta investigación aborda la relación entre el género, la motivación y las actitudes hacia el aprendizaje del inglés, desde una perspectiva que se aparta de la tradicional clasificación binaria del género. Participaron 54 estudiantes de una universidad pública del suroccidente colombiano, inscritos en diferentes niveles de inglés de diversos programas académicos. Se adaptó una encuesta de 39 ítems para evaluar las actitudes y la motivación, y se empleó la versión abreviada del inventario de roles de sexo de Bem para obtener una perspectiva no binaria del género de los y las participantes a partir de los roles de género que adoptan en su cotidianidad. Los resultados revelan que hay una inclinación a identificarse de forma binaria, aunque la mayoría se adhiere estrictamente a roles de género tradicionales. Se encontró una diferencia estadísticamente significativa en tres casos: las personas andróginas presentan puntajes más altos en la motivación instrumental de promoción y las actitudes hacia el aprendizaje del inglés; mientras que las mujeres registran una actitud más favorable hacia la comunidad de habla inglesa en comparación con los hombres. Finalmente, el hecho de que la desviación estándar en las respuestas de los y las participantes –organizadas según sus roles de género– sea menor respalda la limitación de la clasificación binaria tradicional y subraya la necesidad de considerar categorías no binarias para comprender mejor la influencia del género en otras variables.
- Published
- 2024
3. 328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)
- Author
-
Ellen B Gurary, Patricia Marinello, and Carlos Alberto Mayo
- Subjects
Oncology ,medicine.medical_specialty ,Bevacizumab ,business.industry ,medicine.disease ,Olaparib ,Oxaliplatin ,Clinical trial ,chemistry.chemical_compound ,Regimen ,chemistry ,FOLFOX ,Tolerability ,Internal medicine ,medicine ,business ,Progressive disease ,medicine.drug - Abstract
Background Platinum-based regimens, such as FOLFOX (fluorouracil [5-FU], leucovorin, oxaliplatin), are recommended standard of care first-line options in metastatic colorectal cancer (CRC). Maintenance therapy with a less intensive treatment regimen in metastatic CRC patients who do not progress during intensive first-line platinum–based induction therapy can enhance clinical benefit and reduce toxicity associated with long-term exposure to oxaliplatin. The phase 3 CAIRO3 study demonstrated PFS benefit and a trend toward OS benefit in patients who discontinued oxaliplatin and switched to a maintenance regimen of fluoropyrimidine and bevacizumab. Olaparib is an oral PARP inhibitor that has shown efficacy in platinum-sensitive cancers. LYNK-003 is a randomized, open-label, phase 3 trial evaluating the efficacy and safety of olaparib, alone or in combination with bevacizumab, compared with bevacizumab plus 5-FU in patients with unresectable or metastatic CRC that has not progressed following first-line induction with FOLFOX plus bevacizumab. Methods Adult (≥18 years) patients with histologically confirmed unresectable or metastatic CRC that has not progressed following a first-line induction course of ≥6 cycles of FOLFOX plus bevacizumab and who can no longer tolerate oxaliplatin are eligible. Patients are required to have ECOG performance status score 0–1, adequate organ function, and provide tumor tissue for biomarker analysis. Patients will be randomly assigned 1:1:1 to olaparib 300 mg twice-daily (BID) plus bevacizumab 5 mg/kg every 2 weeks (Q2W), olaparib 300 mg BID, or 5-FU 2400 mg/m2 over 46–48 hours Q2W plus bevacizumab 5 mg/kg Q2W. Treatment will be stratified according to response to prior FOLFOX plus bevacizumab induction (stable disease [SD] vs partial response [PR]/complete response [CR]), mutation status (BRAFmut and/or Rasmut vs BRAFwt plus Raswt), and number of cycles of prior FOLFOX plus bevacizumab induction (6–8 vs >8 cycles). Responses will be assessed by computed tomography/contrast-enhanced magnetic resonance imaging per RECIST 1.1 by blinded independent central review (BICR) every 8 weeks during the first year and every 12 weeks thereafter. Study treatments will continue until documented progressive disease, unacceptable toxicity, intercurrent illness that prevents further administration of study intervention, investigator’s decision to discontinue the patient, consent withdrawal, pregnancy, or administrative reasons requiring cessation of study intervention. The primary endpoint is PFS per RECIST 1.1 by BICR and the key secondary endpoint is OS. Additional secondary endpoints are objective response rate and duration of response; safety and tolerability will also be reported. Approximately 525 patients will be enrolled. Results N/A Conclusions N/A Acknowledgements The authors thank the patients and their families for participating in these trials and all investigators and site personnel. Medical writing and/or editorial assistance was provided by Doyel Mitra, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Trial Registration ClinicalTrials. gov, ID number NCT04456699 Ethics Approval The study protocol and all amendments were approved by the relevant Institutional Review Board or ethics committee at each study site. All patients provided written informed consent to participate in the clinical trial.
- Published
- 2020
- Full Text
- View/download PDF
4. Perfis da progesterona sérica durante o ciclo estral de vacas de leite e de corte determinados pela Imunoquimioluminescencia (CLIA) validados pela Imunoabsorção Enzimática (ELISA)
- Author
-
Isabela da Silveira Padilha, Luiz Ernandes Kozicki, Marina de Pauli Thomaz, Carlos Alberto Mayora Aita, Saulo Henrique Weber, Marcio Saporski Segui, Fernando Andrade Souza, Tacia Gomes Bergstein-Galan, and José Carlos dos Santos Breda
- Subjects
Agriculture ,Animal culture ,SF1-1100 - Abstract
O objetivo do estudo foi validar a metodologia da imunoquimioluminescência (CLIA) através da imunoabsorção enzimática (ELISA), determinando a concentração sérica de progesterona em vacas de leite e de corte, durante o ciclo estral. Foram empregadas 30 vacas multíparas não-prenhes (12 da raça Holandesa Preta e Branca e 18 Nelore). Vacas com corpo luteo foram escolhidas com vistas à sincronização do estro e da ovulação, mediante aplicação de 500 mcg de cloprostenol (im). Após a aplicação do luteolitico, os animais foram diariamente submetidos a exames de ultrasssonagrafia (US) ovariana para verificação da ovulação (=dia 01 do ciclo), bem como eram colhidas 02 amostras de sangue para a determinação da P4 pela CLIA e ELISA. As amostras eram centrifugadas para a obtenção do soro, e congeladas a -20 graus para posterior dosagem. Os valores de ELISA e CLIA foram comparados entre si mediante teste t pareado, regressão, ANOVA e coeficiente de determinação (R2), visando a verificação da sensibilidade e correspondência linear. A concentração de P4 originou perfis similares entre as duas metodologias; os perfis de P4 foram mais elevados em bovinos de corte, que nos de leite. A correspondência entre as metodologias resultou em elevado quociente de R2 nos perfis de P4. Concluiu-se que a CLIA pode ser empregada nas determinações hormonais da P4 serica bovina; a CLIA mostrou elevada correspondência linear com os valores da ELISA; a CLIA pode auxiliar as biotecnicas da reprodução nas determinações hormonais.
- Published
- 2024
5. Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study
- Author
-
Ellen B Gurary, Carlos Alberto Mayo, and Patricia Marinello
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,business.industry ,Colorectal cancer ,First line ,medicine.disease ,Oxaliplatin ,Olaparib ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,FOLFOX ,Fluorouracil ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,In patient ,business ,030215 immunology ,medicine.drug - Abstract
TPS156 Background: Patients with metastatic colorectal cancer (CRC) often receive intensive platinum-based regimens, such as FOLFOX (fluorouracil [5-FU], leucovorin, oxaliplatin), as first-line (1L) therapy. For patients who do not progress during 1L platinum-based induction therapy, maintenance with a less intensive regimen can enhance clinical benefit and reduce toxicity. The CAIRO3 study showed a progression-free survival (PFS) benefit and a trend toward overall survival (OS) benefit in patients who received maintenance treatment with a fluoropyrimidine and bevacizumab versus observation following induction treatment of six cycles of platinum-based therapy. Olaparib is an oral PARP inhibitor that has efficacy in platinum-sensitive cancers. The randomized, open-label, phase 3 LYNK-003 trial will investigate the efficacy and safety of olaparib, alone or with bevacizumab, compared with bevacizumab plus 5-FU in advanced CRC that has not progressed during 1L induction treatment with FOLFOX plus bevacizumab. Methods: Patients aged ≥18 years with histologically confirmed metastatic or unresectable CRC that has not progressed after 1L induction of ≥6 cycles of FOLFOX plus bevacizumab and who can no longer tolerate oxaliplatin are eligible. Patients must have an ECOG performance status of 0-1, adequate organ function, and provide tumor tissue for biomarker analysis. Patients will be randomly assigned 1:1:1 to olaparib 300 mg twice-daily (BID), olaparib 300 mg BID plus bevacizumab 5 mg/kg every 2 weeks (Q2W), or bevacizumab 5 mg/kg Q2W plus 5-FU 2400 mg/m2 over 46-48 hours Q2W. Randomization will be stratified by response to prior FOLFOX plus bevacizumab (stable disease vs partial response/complete response), mutation status ( BRAFmut and/or Rasmut vs BRAFwt plus Raswt), and number of prior FOLFOX plus bevacizumab cycles (6-8 vs > 8 cycles). Response will be assessed by computed tomography or contrast-enhanced magnetic resonance imaging per RECIST 1.1 by blinded independent central review (BICR) every 8 weeks for the first 12 months and every 12 weeks thereafter. Treatment will continue until documented disease progression, unacceptable toxicity, investigator’s decision to discontinue, or patient withdrawal. The primary endpoint is PFS per RECIST 1.1 by BICR. Secondary endpoints are OS, objective response rate, duration of response, and safety. Approximately 525 patients will be enrolled. Currently, patients are being enrolled at 18 locations in 4 countries. Clinical trial information: NCT04456699.
- Published
- 2021
- Full Text
- View/download PDF
6. 493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D
- Author
-
Carlos Alberto Mayo, L. Wong, J. Chaves, K. Spencer, R. Kim, Marwan Fakih, Mustapha Tehfe, Elena G. Chiorean, Jeremy S. Kortmansky, A.D. Eyring, J.J. Li, and Petr Kavan
- Subjects
Oncology ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Internal medicine ,medicine ,FOLFIRI ,In patient ,Hematology ,Pembrolizumab ,medicine.disease ,business - Published
- 2020
- Full Text
- View/download PDF
7. Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study
- Author
-
Elena Elez, Hiroya Taniguchi, Takayuki Yoshino, Thierry André, Petr Kavan, Salah-Eddin Al-Batran, Dirk Jaeger, Patrick M Boland, Matthew Burge, Eric Van Cutsem, Carlos Alberto Mayo, Hiroki Hara, Patricia Marinello, Dung T. Le, Yi Cui, Rosine Guimbaud, Tae Won Kim, Ravit Geva, Luis A. Diaz, and Bert H. O'Neil
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Antitumor immunity ,Colorectal cancer ,business.industry ,Pembrolizumab ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,In patient ,business ,030215 immunology - Abstract
4032 Background: Pembrolizumab provides effective antitumor immunity and durable responses in patients (pts) with advanced, colorectal cancer (CRC) with microsatellite instability-high (MSI-H) tumors. We present data on antitumor immunity with pembrolizumab in pts from the phase 2, KEYNOTE-164 study who had approximately 3 years of follow-up, and in pts re-treated after disease progression. Methods: KEYNOTE-164 enrolled pts with metastatic MSI-H CRC, MSI-H status confirmed locally by IHC or PCR, and ≥2 (cohort A) or ≥1 (cohort B) prior lines of therapy (fluoropyrimidine, oxaliplatin, irinotecan, or anti VEGF/EGFR). Eligible pts received pembrolizumab 200 mg Q3W for 2y (35 administrations) or until progression, unacceptable toxicity, or withdrawal. Pts who stopped pembro due to a confirmed CR or after completing 2y of treatment and who progressed after stopping were eligible for re-treatment with up to 17 administrations in the second-course phase, at investigator discretion. Tumor response was assessed Q9W per RECIST v1.1 by independent review. The primary endpoint was ORR. Secondary endpoints included DOR, PFS, OS, and safety. The data cutoff date was Sep 9, 2019. Results: At data cutoff, the median follow-up was 31.4 mo (range, 0.2-47.8) for 61 pts in cohort A and 36.1 mo (0.1-39.3) for 63 pts in cohort B. ORR was 32.8% (3CR, 17PR; 95% CI% 21.3-46.0) for cohort A and 34.9% (8CR, 14PR; 95% CI 23.3-48.0) in cohort B. Median DOR was not reached (NR [range, 6.2-41.3+]) and not reached (range, 3.9+ to 37.1+), respectively. Fifteen pts in cohort A and 17 in cohort B had ongoing responses at data cutoff. Median PFS was 2.3 mo (95% CI 2.1-8.1) with 3-yr PFS rate of 31% in cohort A and was 4.1 mo (2.1-18.9) with 3-yr PFS rate of 34% in cohort B. Median OS was 31.4 mo (21.4-NR) with 3-yr OS rate of 49% in cohort A and was not reached (19.2-NR) with 3-yr OS rate of 52% in cohort B. Nine pts (6 in cohort A, 3 in cohort B) had a second course of treatment. The best response in second course was PR in 1 patient each in cohort A and B. Grade 3-4 drug-related adverse events occurred in 10 (16%) pts in cohort A and 8 (13%) pts in cohort B. No grade 5 drug-related events occurred. Conclusions: After approximately 3 y of follow-up, pembrolizumab continues to provide effective long-term antitumor immunity with durable responses, with small numbers of drug-related adverse events and no drug-related deaths in pts with advanced, MSI-H CRC. Clinical trial information: NCT02460198 .
- Published
- 2020
- Full Text
- View/download PDF
8. Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D
- Author
-
Marwan Fakih, Patricia Marinello, M. Lee, R. Kim, Mustapha Tehfe, L. Wong, J. Chaves, E. G. Chiorean, Petr Kavan, Carlos Alberto Mayo, J.J. Li, K. Spencer, and Jeremy S. Kortmansky
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Systemic chemotherapy ,Stock options ,Hematology ,Pembrolizumab ,Clinical trial ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,Cohort ,medicine ,FOLFIRI ,In patient ,business ,Objective response - Abstract
Background Pembro, a PD-1 inhibitor, confers durable benefit in many tumor types but has limited efficacy in non–microsatellite instability–high (MSI-high)/pMMR mCRC. Chemotherapies that include 5-fluorouracil (5-FU), oxaliplatin and irinotecan, which are commonly used to treat mCRC, may modulate intrinsic tumor immunogenicity and sensitize tumors to immunotherapy agents. In the phase 1b KEYNOTE-651 study (NCT03374254), pembro + mFOLFOX7 (cohort B) or pembro + FOLFIRI (cohort D) was evaluated in patients with non–MSI-high/pMMR mCRC. Methods Patients were ≥18 years with non–MSI-high/pMMR mCRC, Eastern Cooperative Oncology Group performance status 0/1, and no prior systemic chemotherapy for stage IV mCRC (cohort B) or 1 prior therapy including a fluoropyrimidine + oxaliplatin-based regimen (cohort D). Patients received pembro 200 mg every 3 weeks (Q3W) + mFOLFOX7 (oxaliplatin [85 mg/m2]; leucovorin [400 mg/m2]; 5-FU [2400 mg/m2]) Q2W (cohort B) or pembro 200 mg Q3W + FOLFIRI (irinotecan [180 mg/m2]; leucovorin [400 mg/m2]; 5-FU [2400 mg/m2]) Q2W (cohort D). Primary objectives were safety/tolerability and establishment of the recommended phase 2 dose (RP2D); the secondary objective was objective response rate. Results At data cutoff (Feb 18, 2019), 15 patients in cohort B and 16 in cohort D started treatment; median follow-up was 6.8 months (cohort B) and 5.7 months (cohort D). Treatment was discontinued in 4 patients (27%) in cohort B (adverse event [AE], n = 1 [7%]; PD, n = 3 [20%]) and 9 patients (56%) in cohort D (AEs, PD, patient withdrawal; n = 3 [19%] each). There was 1 dose-limiting toxicity in cohort D: grade 3 small-intestinal obstruction. See RP2Ds for cohorts B and D in the Methods section. All patients had ≥1 treatment-related AE (TRAE). Grade 3 TRAEs occurred in 8 patients each in cohort B (53%) and cohort D (50%), most commonly anemia and neutropenia (13% each) in cohort B and neutropenia, diarrhea, fatigue, and leukopenia (13% each) in cohort D. There were no grade 4-5 TRAEs. Efficacy results will be presented. Conclusions Pembro in combination with mFOLFOX7 or FOLFIRI was safe and tolerable in patients with mCRC. Clinical trial identification NCT03374254; Release date: December 15, 2017. Editorial acknowledgement Jacqueline Kolston, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA); Funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Array BioPharma. Funding Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Array BioPharma. Disclosure R. Kim: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Research grant / Funding (institution): Eisai. J. Kortmansky: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche. L. Wong: Research grant / Funding (institution): Astellas Pharma Global Development, Inc./Astellas US, Inc.; Research grant / Funding (institution): BeiGene, Ltd; Research grant / Funding (institution): Exelixis, Inc.; Research grant / Funding (institution): Merck; Research grant / Funding (institution): NovoCure, Inc.; Research grant / Funding (institution): Pierre Fabre Medicament; Research grant / Funding (institution): PledPharma AB; Research grant / Funding (institution): SynCore Biotechnology Co., Ltd.; Research grant / Funding (institution): Halozyme, Inc.; Research grant / Funding (institution): Pharmacyclics, Inc.; Research grant / Funding (institution): TESARO; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Array. M. Tehfe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Celgene; Honoraria (self): Ipsen; Advisory / Consultancy: BMS; Advisory / Consultancy: Takeda; Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Taisho. J.J. Li: Full / Part-time employment: Merck & Co., Inc. M. Lee: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. C. Mayo: Full / Part-time employment: Merck & Co., Inc. P. Marinello: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. E. Chiorean: Advisory / Consultancy: Ipsen; Advisory / Consultancy: Eisai; Advisory / Consultancy: Halozyme; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Array; Advisory / Consultancy: Five Prime; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): AstraZeneca; Travel / Accommodation / Expenses: Halozyme; Research grant / Funding (institution): Merck; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Ignyta/Roche; Research grant / Funding (institution): Stemline; Research grant / Funding (institution): Macrogenetics. All other authors have declared no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
9. Joaquín V. González, la Universidad Nacional de La Plata y la Escuela Platense de Derecho Constitucional
- Author
-
Carlos Alberto Mayón
- Subjects
Joaquín González ,Universidad Nacional de La Plata ,Escuela Platense de Derecho Constitucional ,Law ,Law in general. Comparative and uniform law. Jurisprudence ,K1-7720 - Abstract
Joaquín V. González, de quien se cumplen cien años de su fallecimiento, fue uno de los más importantes escritores, políticos y constitucionalistas de la Argentina. Sus aportes fueron fundamentales para la Ciencia Política, el Derecho Constitucional y el Estudio de la Historia Argentina. Fundó la Universidad Nacional de La Plata, con características totalmente innovadoras, y la Escuela Platense de Derecho Constitucional.
- Published
- 2023
10. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
- Author
-
Min-Hee Ryu, Christian Caglevic, Soonmo Peter Kang, Wasat Mansoor, M. Di Bartolomeo, Raymond S. McDermott, X. Chen, H.C. Chung, E. Schacham-Shmueli, Kohei Shitara, Kei Muro, Y-J. Bang, Mario Mandalà, A. Ohtsu, Tomasz Olesinski, Mustafa Ozguroglu, E. Gökkurt, Carlos Alberto Mayo, Lorenzo Fornaro, and Charles S. Fuchs
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,Cancer ,Hematology ,Pembrolizumab ,Gastroesophageal Junction ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Paclitaxel ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,business ,Previously treated - Published
- 2018
- Full Text
- View/download PDF
11. Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial
- Author
-
Hyun Cheol Chung, Raymond S. McDermott, Kei Muro, Maria Di Bartolomeo, Tomasz Olesinski, Eray Goekkurt, Mustafa Ozguroglu, Wasat Mansoor, Yung-Jue Bang, Christian Caglevic, Mario Mandalà, Carlos Alberto Mayo, Lorenzo Fornaro, Charles S. Fuchs, Kohei Shitara, Atsushi Ohtsu, Einat Shacham-Shmueli, S. Peter Kang, X. Chen, and Min-Hee Ryu
- Subjects
Antitumor activity ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,Cancer ,Pembrolizumab ,medicine.disease ,Gastroesophageal Junction ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Paclitaxel ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,In patient ,Previously treated ,business ,030215 immunology - Abstract
4062Background: Pembro has shown promising antitumor activity in patients (pts) with pretreated G/GEJ cancer. KEYNOTE-061 (NCT02370498) was a global phase 3 study of pembro vs PTX for previously tr...
- Published
- 2018
- Full Text
- View/download PDF
12. Variables predictoras del desempeño escolar en exámenes estandarizados de inglés: Evidencias desde el examen de Estado en Colombia
- Author
-
Diana Milena Gutiérrez Duque and Carlos Alberto Mayora Perní
- Subjects
análisis multivariado ,enseñanza del inglés como lengua extranjera ,evaluación ,programa nacional de bilingüismo ,pruebas estandarizadas ,Education (General) ,L7-991 ,Social sciences (General) ,H1-99 - Abstract
En Colombia se ha incluido un dominio masivo del inglés entre las metas estratégicas, dando pie al programa Colombia Bilingüe y la inclusión de una prueba estandarizada de inglés en el examen de Estado. Este estudio buscó determinar el efecto de diferentes variables institucionales sobre los resultados de esta prueba, a través del método cuantitativo de diseño ex post facto. Se analizaron los resultados en el examen de inglés de 87 instituciones educativas de una de las ciudades más importantes del país. Las variables independientes incluyeron la participación en programas de fortalecimiento del bilingüismo, características institucionales y el desempeño en lectura crítica, mientras el resultado en el componente de inglés fue la variable dependiente. Para el análisis de los datos se utilizaron el ANOVA de una vía y la regresión lineal multivariada. Los resultados muestran que no hay diferencia estadísticamente significativa en el desempeño entre las escuelas beneficiadas por el plan Colombia Bilingüe y aquellas no beneficiadas. Solo la jornada de estudios arrojó resultados significativos. El modelo de regresión demostró que el desempeño en lectura crítica es el mejor predictor de la variable dependiente, lo que sugiere una relación entre las habilidades en la lengua materna y la lengua extranjera.
- Published
- 2021
- Full Text
- View/download PDF
13. Análisis del currículo del área de inglés en escuelas oficiales de Cali
- Author
-
Carlos Alberto Mayora and Diana Milena Gutiérrez
- Subjects
lengua extranjera ,enseñanza de idiomas ,planes de estudio ,instituciones de enseñanza ,política lingüística ,Romanic languages ,PC1-5498 ,Philology. Linguistics ,P1-1091 - Abstract
En el presente estudio se reportan la descripción y el análisis del currículo del área de inglés de 28 Instituciones Educativas Oficiales de la ciudad de Cali. Se trata de un estudio de caso múltiple con unidad de análisis incrustada y de tipo cerrado cuyos principales datos los constituyen los proyectos educativos institucionales, planes de área y planes de aula de las instituciones participantes. Se encontró que la mayoría de las instituciones no han realizado una actualización constante de sus curricula, que la lengua extranjera tiene poca o ninguna visibilidad en los documentos institucionales, que ha habido una incorporación superficial de los lineamientos curriculares emanados del Ministerio de Educación Nacional y que existe poca articulación en la estructura curricular entre los niveles educativos. A partir de los resultados se presentan recomendaciones pertinentes para mejorar la estructuración curricular del área de inglés.
- Published
- 2019
- Full Text
- View/download PDF
14. El currículo del área de inglés de cuatro instituciones educativas oficiales de Cali: un estudio de caso múltiple
- Author
-
Margareth Lorena Marmolejo and Carlos Alberto Mayora
- Subjects
currículo ,enseñanza del inglés ,lenguas extranjeras ,política lingüística ,Education (General) ,L7-991 - Abstract
El presente artículo tiene por objetivo describir la estructura curricular del área de inglés de cuatro instituciones educativas oficiales de la ciudad de Cali, Colombia. Para este fin se hizo la revisión de los proyectos educativos institucionales, planes de área y aula de inglés de las instituciones seleccionadas. La presente investigación es de corte cualitativo con diseño de estudio de casos múltiple flexible con unidad de análisis holística sustentada en el análisis documental. La descripción de cada caso incluyó el modelo pedagógico de la institución, el enfoque metodológico para la enseñanza de lengua, y la descripción de los diferentes componentes curriculares (metas, contenidos, metodología, materiales y evaluación) y cómo se formulan y articulan cada uno de estos componentes. Como resultado encontramos que existen inconsistencias entre lo conceptual y lo práctico, falta articulación entre los diferentes componentes curriculares (contenidos que no se corresponden con las metas), falta de especificidad en la descripción de la metodología, las actividades y las técnicas e instrumentos de evaluación. Se observó además una integración parcial y desarticulada de los documentos curriculares centrales como los Derechos Básicos de Aprendizaje y el Currículo Sugerido para Inglés. Se discuten algunas implicaciones de los hallazgos y se presentan algunas recomendaciones para fortalecer la enseñanza del inglés desde los documentos institucionales de las escuelas.
- Published
- 2020
- Full Text
- View/download PDF
15. Los Betlemitas en Buenos Aires: Convento, economia, y sociedad (1748-1822)
- Author
-
A. J. Bauer and Carlos Alberto Mayo
- Subjects
Cultural Studies ,History - Published
- 1992
- Full Text
- View/download PDF
16. Locus of Control and Academic Achievement in Higher Education: A Bibliographic Review
- Author
-
Carlos Alberto Mayora-Pernía and Nelly Fernández de Morgado
- Subjects
Locus de control ,rendimiento académico ,estudiantes universitarios ,Education ,Special aspects of education ,LC8-6691 - Abstract
The purpose of this paper is to provide a bibliographic review about the relation between locus of control (LC) and academic achievement in higher education students. Online repositories were the main source of information. The most important findings show that, (a) the LC construct has evolved from being a dichotomist to a multidimensional variable; (b) there are very few recent international studies and none of them covers Latin-America; (c) interdisciplinary research is scarce and the absence of the qualitative approach is noticeable; and, (d) whether direct or indirectly, most studies show a relation between LC and academic achievement in higher education. These findings show the need to address this topic in Latin America. It is suggested to conduct interdisciplinary, longitudinal, qualitative, and quantitative studies under the supervision of institutions and teachers; the results would be used to design interventions to improve que quality of education.
- Published
- 2015
- Full Text
- View/download PDF
17. Aportes de la Lingüística Aplicada al Estudio del Poder
- Author
-
Carlos Alberto Mayora Pernía
- Subjects
poder ,lingüística aplicada ,geopolítica ,análisis del discurso ,Romanic languages ,PC1-5498 ,Philology. Linguistics ,P1-1091 - Abstract
Existen dos marcadas tendencias en las ciencias sociales actualmente: a) un creciente interés en el estudio del poder como fenómeno sociopolítico; b) el abordaje interdisciplinario de éste y otros temas sociales. No obstante, en recientes compilaciones sobre el tema del poder, la lingüística aplicada no ha sido incluida, hecho que representa un gran vacío dada la natural relación entre lenguaje y poder, y el carácter práctico e interdisciplinario propio de esta disciplina. Aquí se reseñan tres áreas muy representativas de la lingüística aplicada que arrojan luces a las relaciones de poder dentro de las naciones, pero también entre ellas.
- Published
- 2015
- Full Text
- View/download PDF
18. Sociedad rural y militarización de la frontera en Buenos Aires, 1737-1810
- Author
-
Carlos Alberto Mayo
- Subjects
Cultural Studies ,History - Published
- 1987
- Full Text
- View/download PDF
19. Formação in vitro de túbulos capilares a partir de células de sangue de cordão umbilical humano com perspectivas para aplicação terapêutica In vitro formation of capillary tubules from human umbilical cord blood cells with perspectives for therapeutic application
- Author
-
Alexandra Cristina Senegaglia, Paulo Roberto Slud Brofman, Carlos Alberto Mayora Aita, Bruno Dallagiovanna, Carmen Lúcia Kuniyoshi Rebelatto, Paula Hansen, Fabiane Barchiki, and Marco Aurélio Krieger
- Subjects
Células endoteliais ,Proliferação de células ,Transplante de células-tronco de sangue do cordão umbilical ,Neovascularização Fisiológica ,Endothelial cells ,Cell proliferation ,Cord blood stem cell transplantation ,Neovascularization, physiologic ,Surgery ,RD1-811 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
OBJETIVO: As células progenitoras endoteliais (CPE), caracterizadas pelo marcador CD133+, contribuem para a neovascularização, e o aumento no número dessas células pode ser uma ferramenta terapêutica promissora. O sangue de cordão umbilical humano contém um número significante de CPE, sugerindo a possibilidade do uso destas células para a revascularização de tecidos isquêmicos. O objetivo desse trabalho foi analisar a funcionalidade das células CD133+ diferenciadas in vitro. MÉTODOS: As células diferenciadas foram caracterizadas por citometria de fluxo; a expressão do mRNA de VEGF foi avaliada por RT-PCR e a funcionalidade, por meio de ensaios de formação de túbulos capilares. RESULTADOS: As células diferenciadas perderam os marcadores de CPE, mantiveram em níveis baixos os marcadores das linhagens hematopoética e monocíticas e aumentaram a expressão dos marcadores de células endoteliais adultas. As células diferenciadas apresentaram transcritos no mRNA de VEGF e mostraram-se capazes de formar túbulos capilares in vitro. CONCLUSÃO: As células CD133+ diferenciadas in vitro em células endoteliais demonstraram serem funcionalmente ativas, abrindo perspectiva para seu uso futuro em aplicações terapêuticas.OBJECTIVE: Endothelial progenitor cells (EPC) caracterized by the CD133+ marker, contribute to the neovascularization. Increasing EPC number in vitro could be a promising therapeutic tool. Human umbilical cord blood maintains a significant number of EPC, suggesting the possibility to use these cells to induce the revascularization of ischemic tissues. The aim of this study was to analize the in vitro function of differentiated CD133+ cells. METHODS: Cells were characterized by flow cytometry, VEGF mRNA expression was evaluated by the RT-PCR analysis and the functionally by essays of capillary tubes formation. RESULTS: Differentiated cells lost EPC markers, maintained low levels of markers for hematopoietic and monocytic cell lines and increased the expression of adult endothelial cell markers. Differentiated cells expressed VEGF mRNA and were capable to induce in vitro capillary tubules formation. CONCLUSION: CD133+ cells differentiated into endothelial cells in vitro are functionally active initiating the possibility of their use in future therapeutic applications.
- Published
- 2008
- Full Text
- View/download PDF
20. Pensamiento crítico y comprensión de la lectura en un curso de inglés como lengua extranjera
- Author
-
Nelly Yiveline Fernández de Morgado, Carlos Alberto Mayora Pernía, and Rubena St.Louis
- Subjects
pensamiento crítico ,comprensión de lectura ,enseñanzaaprendizaje del inglés como lengua extranjera ,Ennis-Weir Critical Thinking Essay Test. ,Philology. Linguistics ,P1-1091 ,French literature - Italian literature - Spanish literature - Portuguese literature ,PQ1-3999 - Abstract
Existe gran interés en el diseño de entornos de aprendizaje del inglés como lengua extranjera que fomenten el desarrollo del pensamiento crítico. Para ello es necesario comprender la naturaleza de las relaciones entre los elementos que se conjugan en el quehacer educativo. En este sentido, el presente estudio busca determinar la relación entre las habilidades para el pensamiento crítico (HPC) y la comprensión de la lectura (CL) de textos científico-técnicos en inglés, de un grupo de estudiantes de inglés como lengua extranjera de la Universidad Simón Bolívar, Venezuela. Es un estudio exploratorio enmarcado en el paradigma cuantitativo, ex post facto, con diseño transversal. Se utilizó el The Ennis-Weir Critical Thinking Essay Test para medir las HPC y la prueba de logro de CL departamental para la competencia lingüística. Los resultados muestran que la relación entre las HPC y la CL es baja, positiva y significativa. También se evidenció un desempeño muy bajo tanto en las HPC como en la CL. Los hallazgos sugieren que la lectura es una herramienta útil para fomentar las HPC; no obstante, el curso debe ser afinado para mejorar su efectividad. Se discuten implicaciones pedagógicas de los resultados y se ofrecen sugerencias para futuras investigaciones.
- Published
- 2015
- Full Text
- View/download PDF
21. 3. Variables para la elaboración del perfil de estudiantes de inglés: carreras cortas en la USB
- Author
-
Carlos Alberto Mayora (USB)
- Subjects
perfil de ingreso ,variables demográficas ,formación preuniversitaria en inglés ,Education (General) ,L7-991 ,History of education ,LA5-2396 ,Special aspects of education ,LC8-6691 ,Theory and practice of education ,LB5-3640 - Abstract
El presente trabajo es un avance de una investigación más amplia acerca del perfil de ingreso a los programas de inglés de los estudiantes de carreras cortas de la Universidad Simón Bolívar, sede Sartenejas. Este avance se concentra especialmente en el proceso de selección y justificación de las variables a incluir en dicho perfil. Para seleccionar las variables se realizó primero una investigación documental sobre los perfiles de aprendices de lenguas extranjeras y de estudiantes universitarios en el ámbito nacional e internacional. Luego se desarrolló un estudio piloto de tipo descriptivo y exploratorio a fin de refinar las variables. Como resultado, se tiene que la complejidad del proceso de aprendizaje de lenguas extranjeras requiere la elaboración de un perfil más amplio del estudiante, en donde se considere éste como individuo biopsicosocial y no sólo desde una perspectiva lingüística.
- Published
- 2015
22. O EFEITO DO ALOPURINOL NA VIABILIDADE DE HEPATÓCITOS MURINO, IN VITRO
- Author
-
Sandra Maria Ferreira, João Eduardo Leal Nicoluzzi, João Carlos Domingues Repka, Carlos Alberto Mayora Aita, and Carlos Fernandes Alves
- Subjects
Hepatócitos ,Transplante ,Cultura ,Specialties of internal medicine ,RC581-951 ,Special situations and conditions ,RC952-1245 ,Surgery ,RD1-811 - Abstract
Objetivo: Observar o efeito protetor do alopurinol nos hepatócitos em cultura, pelo seu efeito inibidor da xantina oxidase na geração de radicais livres de oxigênio. Métodos: Os hepatócitos foram isolados a partir de fígado de ratos, por dissociação enzimática segundo a técnica descrita em 1969 e modificada em 1976. As técnicas cirúrgicas foram realizadas na sala de cirurgia experimental da PUC/PR. Foram realizadas contagens iniciais, e a viabilidade foi calculada pelo teste de exclusão pelo azul de trypan. As concentrações de albumina e de malondialdeído foram analisadas por testes bioquímicos colorimétricos. Resultados: O rendimento dos hepatócitos isolados após digestão enzimática utilizando-se colagenase foi de 1,5X106 cel/gr/fígado para GC e 1,7 X106 cel/gr/ fígado para GE, com viabilidade inicial de 60% para ambos os grupos. O resultado para albumina foi de 0,1868 mg/ml (+/- 0,023) para GC e 0,1384 mg/ml (+/- 0,019) para GE. Para o malondialdeído, os resultados foram 0,3963 nmol/mg de proteínas (+/-0,0 98) para GC e 0,2040 nmol/mg de proteínas (+/-0,058) para GE. Conclusão: O alopurinol diminui a produção do malondialdeído, demonstrando menor estresse oxidativo nas células tratadas previamente com o medicamento. Porém, essa diminuição não chega a interferir na manutenção da viabilidade celular.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.